|
|
 |
|
Viewing report
|
|
|
|
Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia
Datamonitor, June 2009, Pages: 123
The Saudi Arabian pharmaceutical sector is becoming increasingly attractive for multinationals to enter driven by the expansion of private healthcare and altering patient demographics; and also for domestic generics companies as the government looks to evolve its cost saving strategies.
Scope
- Overview of challenges faced by the Saudi Arabian healthcare system and a review of the healthcare financing system reforms
- Analysis of trends observed in the pharmaceutical sector and the development of the healthcare insurance sector
- Update of healthcare reforms undertaken in the Kingdom and thought-leader insights into future changes to be implemented
- Commercial implications of the reforms for insurers, multinational and domestic pharma companies, supported by Datamonitor strategic recommendations
Highlights of this title
Healthcare reforms in Saudi Arabia will increase access to healthcare services and pharmaceuticals as the penetration of cooperative health insurance increases across the Kingdom. Datamonitor forecasts this will result in a significant increase in overall expenditure on drugs; however there will be a greater shift towards generics use.
As competition increases, insurers will attempt to increase profits by implementing cost containment measures such as pharmacoeconomic drug evaluations, generic substitution and formulary lists. However, strong underwriting policies, optimal pricing premiums, and delivering quality care to members will remain critical.
Increasingly westernized lifestyles have driven up levels of chronic disease, enhancing the need for drug intervention, with lifestyle products dominating the retail market. Many branded drugs despite their off patent status still command market leading sales and positive growth, underlining the preference for branded drugs in the Saudi market.
Key reasons to purchase this title
- Understand the Saudi healthcare market and the strategic implications of future reforms and how these will affect your business
- Identify opportunities for mutually beneficial relationships between your firm and insurers which are becoming increasingly powerful stakeholders
- Gain insight into investment opportunities and create compelling cases for strategic changes in your organization to adapt to the evolving market
Customers who bought this item also bought
Pharmaceutical Pricing and Reimbursement in Canada
Pharmaceutical Pricing, Reimbursement, and Market Access in Poland, Romania and Ukraine
The Pharmaceutical Market: Saudi Arabia
Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies
Market Access Korea - Breaking into the Developed World’s Fastest Growing Pharmaceutical Market
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
Pricing, Reimbursement, and Market Access in the BRIC-MT Markets
Pharmaceutical Pricing, Reimbursement and Market Access News in the First Quarter of 2010
Pharmaceutical Pricing, Reimbursement, and Market Access News in the First Quarter of 2011
Healthcare Reform in China
|
|
|
|
